Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 4Gastrointestinal 3Sarcoma 2Head & Neck 2Genitourinary 2Endocrine 2Dermatologic 2Thoracic 1Other solid neoplasm 1CNS 1Breast 1

Conditions

Advanced Solid Tumors 173Advanced Solid Tumor 150Solid Tumor 129Mesothelioma 88Mesothelioma, Malignant 82Solid Tumors 79Hematopoietic and Lymphatic System Neoplasm 47Solid Tumor, Adult 35Carcinoma, Non-Small-Cell Lung 32Retinoblastoma 29Ovarian Neoplasms 26Melanoma 24Colorectal Neoplasms 22Pancreatic Neoplasms 21Stomach Neoplasms 20Sarcoma 20Lung Neoplasms 19Carcinoma, Renal Cell 18Uterine Cervical Neoplasms 16Esophageal Neoplasms 16Neoplasms 15Malignant Solid Neoplasm 15Neoplasm Metastasis 14Hematopoietic and Lymphoid System Neoplasm 14Advanced or Metastatic Solid Tumors 14Triple Negative Breast Neoplasms 13Solid Tumor Malignancies 13Small Cell Lung Carcinoma 13Advanced Malignant Solid Tumor 13Urinary Bladder Neoplasms 12

Interventions

atezolizumab 1Immunoglobulin G 1Disulfides 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Adenocarcinoma, Mucinous × Other solid neoplasm × 1 year × Clear all
NCT03074513 2026-03-11

Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
133 enrolled
DermatologicEndocrineHead & NeckOther solid neoplasmThoracic

Nasopharyngeal Carcinoma, Mesothelioma, Malignant, Adenocarcinoma, Mucinous, Adenoma, Islet Cell, Nasopharyngeal Neoplasms, Carcinoma, Merkel Cell, Carcinoma, Neuroendocrine

Data powered by HemOnc (CC BY 4.0) Colophon âš¡